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Abstract: The translocator protein (TSPO) (18 kDa) is an emerging drug target for the treatment of numerous 
pathologies including cancer and neurodegenerative disease. However, our limited knowledge of TSPO 
binding site(s) has hindered the development of TSPO ligands with potential therapeutic effects. We have 
synthesized a series of pyrrolobenzoxazepines (1-10) to better characterize the interaction of ligands with the 
TSPO across species, and to determine their functional profiles. All ligands 1-10 displaced the binding of 
[
3
H]PK 11195 to the TSPO at nanomolar concentrations, with discrepancies in binding affinity between rat and 
human TSPO. Interestingly, non-linear regression analysis revealed that some ligands bound to the protein 
with a Hill slope not equal to 1.0, suggesting possible additional TSPO binding sites with allosteric effects. 
However, this trend was not conserved between rat and human. When tested for their effects on pregnenolone 
production in rat C6 glioma cells, nitric oxide release in murine microglia, and cell proliferation in human MCF-7 
breast cancer cells, the pyrrolobenzoxazepines (40 µM) displayed functional effects which did not correlate to 
the binding trend observed in competition assays. We propose that consideration of species differences and 
binding site cooperativity, plus optimization of currently accepted functional assays, will aid in the development 
of drugs targeting TSPO that can be used as therapeutics for human disease.  
Keywords: Binding cooperativity, neuroprotection, pyrrolobenzoxazepines, radioligand binding, structure activity 
relationships, translocator protein (TSPO). 
INTRODUCTION 
The TSPO is primarily found in mitochondrial 
membranes, where its best characterized role is the 
rate-limiting regulation of steroid biosynthesis. 
Cholesterol transport from the outer to inner 
mitochondrial membrane and subsequent conversion 
to pregnenolone is activated upon ligand binding to the 
TSPO [1]. Hence, measurement of pregnenolone 
production is used routinely for the functional 
evaluation of new TSPO ligands. However, the TSPO 
has been implicated in other complex cellular functions 
such as mediating apoptotic and necrotic cell death [1]. 
Additionally, the TSPO is highly expressed in both 
neurodegenerative diseases and cancer [1, 2], with 
protein levels correlated to microglial activation and 
aggressive metastatic behavior [3]. TSPO ligands 
exercise both neuroprotective and anti-tumor effects in  
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these pathologies, by inhibiting the production and 
release of inflammatory mediators from activated 
microglia [4], and by causing cell-cycle arrest or 
induction of apoptosis [5, 6], respectively. Thus, the 
TSPO is implicated in both the development of disease 
and as a drug target for treatment [1, 2, 5]. 
Two ligands have been essential for characterizing 
the TSPO; the benzodiazepine Ro 5-4864 and the 
isoquinoline carboxamide PK 11195, both of which are 
selective for the TSPO and display nanomolar binding 
affinities [7-9]. While these ligands display saturable 
binding and reciprocal competition in radioligand 
binding assays [7, 9, 10], this is not consistent across 
species [11] and can be modified separately in both rat 
and human [10]. Furthermore, site-directed 
mutagenesis studies suggest certain residues in the 
first putative loop of TSPO are important for the binding 
of Ro 5-4864, but not PK 11195 [12]. These findings 
prompted the theory of binding site heterogeneity 
and/or multiple binding sites at TSPO, the implications 
of which have not been thoroughly explored. 
Consequently, while a range of structurally diverse 
synthetic and semisynthetic TSPO ligands have been 
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developed, thorough characterization of their 
interaction with the TSPO protein is lacking.  
To better understand the interaction of ligands with 
TSPO, we synthesized ten pyrrolobenzoxazepines (1-
10) (Table 1) based on previously reported structure-
activity relationships [13]. We screened these ligands 
for affinity against [
3
H]PK 11195 in competitive binding 
assays in both rat and human TSPO. In addition, we 
analyzed the curves by non-linear regression to yield a 
Hill slope value, whereby a slope not equal to 1.0 
indicates more than a simple competitive binding 
interaction, suggesting the possibility of additional sites 
or allosteric modulation. Additionally, we measured 
three therapeutically relevant functional parameters, 
including the ability of the ligands to modulate 
pregnenolone and nitric oxide (NO) release, and anti-
proliferative effects, in an attempt to draw correlations 
between the binding interaction of the ligands with 
TSPO and the downstream functional consequences.  
RESULTS AND DISCUSSION 
In the present study, we evaluated the binding 
affinity, Hill slopes, and functional effects of ten new 
pyrrolobenzoxazepines as ligands for the TSPO. 
Furthermore, to the best of our knowledge, this is the 
first time this class of compounds has been tested for 
binding affinity for human TSPO. This study also 
emphasizes the importance of considering the concept 
of possible alternate binding sites in routine assays for 
the screening of new TSPO ligands.  
The affinity of synthesized pyrrolobenzoxazepines 
for TSPO was determined by competition binding 
assays against [
3
H]PK 11195, using mitochondrial 
fractions from rat kidney and human embryonic kidney 
(HEK293) cells. Subtle structural differences 
dramatically altered the binding profile of compounds 1-
10. Significant differences in binding affinity between 
rat and human TSPO were also revealed (Table 1). 
Accordingly, compound 1 showed a 5.3-fold higher 
binding affinity in human than in rat, while compounds 
4, 6-8 and 10 showed a much higher binding affinity in 
rat than in human (4: 67.6-fold; 6: 5.6-fold; 7: 5.6-fold; 
8: 412.1-fold; 10: 24.1-fold). Compounds 2-3, 5 and 9 
presented with similar binding affinities in rat and 
human. For comparison, cold PK 11195 had a similar 
binding affinity in rat and human cells, while Ro 5-4864 
displayed a 15.7-fold higher binding affinity in rat than 
in human cells, consistent with previous studies [14]. 
These findings are of particular interest, since the 
TSPO is highly conserved, with an amino acid 
homology of 80% between rat and human [12]. Thus, 
the subtle structural differences between rat and 
human TSPO have a significant impact on the residues 
Table 1. General Structure and Cross-Species Binding Trends for the Compounds Synthesized 
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Compound X R R' R" 
Ki nM 
(rat)
a
 
Ki nM 
(human)
a 
Hill slope 
(rat) 
Hill slope 
(human) 
1 N H CH3 OCH3 68.52 ± 2.0 12.93 ± 1.41 0.99 ± 0.09 0.66 ± 0.05 *** 
2 N H CH2CH3 OCH3 0.43 ± 0.04 0.91 ± 0.08 0.75 ± 0.05 * 1.11 ± 0.08 
3 CH H CH3 OCH3 1.50 ± 0.10 0.89 ± 0.08 0.93 ± 0.08 0.73 ± 0.05 *** 
4 CH H CH2CH3 OCH3 0.45 ± 0.06 30.41 ± 2.72 2.34 ± 0.15 *** 2.11 ± 0.50 *** 
5 CH H CH3 F 0.33 ± 0.03 0.55 ± 0.06 1.09 ± 0.12 1.07 ± 0.12 
6 CH H CH2CH3 F 0.40 ± 0.05 2.26 ± 0.34 1.03 ± 0.08 0.93 ± 0.11 
7 CH Cl CH3 OCH3 9.69 ± 0.80 54.44 ± 4.30 1.41 ± 0.13 *** 1.15 ± 0.10 
8 CH Cl CH2CH3 OCH3 0.14 ± 0.01 57.69 ± 5.33 1.29 ± 0.09 ** 0.91 ± 0.08 
9 CH CH3 CH3 OCH3 22.19 ± 2.0 26.19 ± 2.09 0.99 ± 0.08 1.17 ± 0.10 
10 CH CH3 CH2CH3 OCH3 0.68 ± 0.05 16.39 ± 1.95 0.84 ± 0.07 0.77 ± 0.07 ** 
PK 11195     9.3 ± 0.50 7.11 ± 0.35 1.01 ± 0.11 0.99 ± 0.05 
Ro 5-4864     23.0 ± 3.0 360.7 ± 23.62 0.99 ± 0.10 0.87 ± 0.07 
a
Ki values represent binding affinities from competition binding experiments against [
3
H]PK 11195 in either rat kidney or HEK293 cells. Values represent the mean ± 
SEM of at least three independent experiments carried out in duplicate. 
*p<0.05 ** p<0.01; *** p<0.001, significantly different to a one-site competition curve will Hill slope equal to 1.0 using extra sum-of-squares F test. 
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involved in ligand binding, and possibly also functional 
activity across species. 
Non-linear regression analysis of [
3
H]PK 11195 
displacement in both HEK293 cells and rat kidney 
revealed more than a simple competitive binding 
interaction with [
3
H]PK 11195. While some ligands 1-10 
bound with a slope equal to 1.0 (Table 1), indicating 
competitive binding to a single population of sites, other 
ligands bound with a slope less or greater than 1.0 
(Table 1), denoting a more complex binding profile. 
Possibilities include binding to multiple sites with 
different affinities, or negative/positive allosteric 
interactions. However, different Hill slope values were 
observed for most compounds across rat and human 
TSPO (Table 1), again suggesting that binding differs 
significantly between the two species.  
Analysis of competition curves has previously been 
undertaken for the endogenous TSPO ligand 
protoporphyrin IX (PPIX), which is able to displace [
3
H] 
PK 11195 with a slope of 2.0 [15]. Interestingly, PPIX 
binding is also dose-dependently associated with 
TSPO dimer formation [15]. Thus, it is plausible to 
suggest that 4 in human, and 4, 7-8 in rat, with a similar 
slope, drive the formation of the TPSO dimer which 
may be responsible for an active form of the protein 
[16, 17]. Alternatively, a Hill slope of 2.0 may indicate 
multiple binding sites involved in positive allosteric 
modulation. We believe that further research into 
binding site cooperativity will provide a better 
understanding of structure-activity relationships at 
TSPO. While this study revealed no clear structural 
requirements to account for the variation in slope, this 
may be due to the small number of compounds in this 
series. 
In addition to displacement of [
3
H]PK 11195, three 
functional readouts of the TSPO ligands 1-10 were 
assessed. Firstly, the induction of pregnenolone 
release from rat C6 glioma cells, secondly NO release 
from murine BV2 microglial cells and thirdly anti-
proliferative effects in MCF-7 human breast cancer 
cells. PK 11195 stimulated pregnenolone release from 
rat C6 glioma cells 37 ± 1% (p<0.001) above baseline 
levels of vehicle treated control (Fig. 1), consistent with 
previous reports [18]. Interestingly, despite having the 
lowest binding affinity of all tested compounds to rat 
TSPO (Table 1), compound 1 was the most potent 
stimulator of pregnenolone release (106 ± 18% vs. 
control; p<0.0001). Compounds 2-3 and 10 had similar 
effects on pregnenolone release to PK 11195, while 7-
8 (p<0.01) and 9 (p<0.05) affected pregnenolone 
release significantly less than PK 11195. Compounds 
4-6 had no effect on pregnenolone release. Thus, the 
pyrrolobenzoxazepines display a variety of effects on 
pregnenolone release, at a range consistent with 
previous studies using this class of compounds [13]. 
The TSPO has been shown to regulate NO release 
from activated microglia [4], giving rise to a number of 
ligands with potential neuroprotective effects. Thus, we 
determined the amounts of NO released from activated 
murine BV2 microglial cells upon treatment with PK 
11195, 2-3, 5 and 9. Consistent with previous reports 
[4], PK 11195 significantly inhibited the production of 
NO in activated BV2 microglial cells by 57 ± 2 % 
compared to vehicle in LPS treated controls (p<0.0001) 
(Fig. 2). Similarly, all tested pyrrolobenzoxazepines 
inhibited NO release from activated BV2 microglia 
(p<0.0001 vs. control) (Fig. 3). Of note, 2, which 
showed the highest activity of the 
pyrrolobenzoxazepines tested here in regards to 
pregnenolone release (see Fig. 1), also showed the 
most potent inhibition of NO release, by 74 ± 6 % 
compared to vehicle in LPS treated controls 
(p<0.0001). This was significantly more inhibition than 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Effect of 40 µM ligands on pregnenolone release in rat C6 glioma cells.
 
Experimental data represent the increase in 
pregnenolone production above baseline, denoted by mean ± SEM of at least three independent experiments. * p<0.05; ** 
p<0.01; *** p<0.001, significantly different to PK 11195 using one-way ANOVA and Bonferroni’s post-hoc test. 
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that achieved with PK 11195 (p<0.0001). Conversely, 5 
that did not increase pregnenolone release above 
baseline (see Fig. 1), inhibited NO release by 66 ± 3 % 
compared to LPS treated control (p<0.0001), and was 
therefore significantly more effective than PK 11195 
(p<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effect of selected pyrrolobenzoxazepines and PK 
11195 (40 µM) on NO production from activated BV2 
microglial cells. Data are expressed as the percentage 
inhibition of NO production, compared to LPS-treated 
controls. Bars represent mean ± SEM of at least 3 
independent experiments carried out in duplicate. * p<0.05; 
**p<0.01; *** p<0.001, significantly different from PK 11195 in 
the presence of LPS, using one-way ANOVA and 
Bonferroni’s post-hoc test. All compounds tested inhibited NO 
release to a level which was significantly different from 
vehicle alone in the presence of LPS (p<0.001).  
The mechanism by which TSPO ligands mediate 
their neuroprotective effects is proposed to be through 
the inhibition of microglial activation resulting in 
inhibition of cytokine and inflammatory mediator 
release [1]. Of interest, previous studies have 
correlated an increase in steroid synthesis with nerve 
regeneration [19-21] for both endogenous TSPO 
ligands [19, 20] and those tested in models of 
neuropathy in rats [20]. However, our reported 
inhibition of NO release occurred without any positive 
correlation to increases in pregnenolone release, 
suggesting that neuroprotective effects caused by the 
pyrrolobenzoxazepines occur independent of this 
mechanism. Our study may be limited by the mediator 
tested as an indicator of microglial activation, and 
future work should look to measure release of other 
cytokines from activated microglia. 
TSPO ligands such as Ro 5-4864 and PK 11195 
have anti-proliferative effects in various cancer cell 
lines, including the MCF-7 human breast cancer cell 
line [22]. Therefore, we also compared the anti-
proliferative effects of PK 11195 and 1-10 in MCF-7 
cells using the sulforhodamine B assay. PK 11195 
impaired the proliferation of MCF-7 cells by 54 ± 3% 
compared to vehicle treated control (Fig. 3). 
Interestingly, all compounds showed anti-proliferative 
effects significantly different from the vehicle treated 
control (p<0.0001) (Fig. 3). However, compounds 1-8 
and 10 were significantly better anti-proliferative agents 
when compared to PK 11195. Notably, compound 8 
was the most potent inhibitor, reducing cell proliferation 
by 90 ± 1% compared to controls, while having the 
lowest affinity of all the pyrrolobenzoxazepine ligands 
tested for human TSPO (Table 1). Thus, 
pyrrolobenzoxazepines showed anti-proliferative 
effects, however, of variable potency. 
It has been previously suggested that anti-
proliferative effects caused by TSPO ligands may be 
mediated by other proteins within the cell [5]. 
Nevertheless, TSPO knockdown in MCF-7 breast 
cancer cells results in cell cycle arrest, and ultimately, 
reduced cell proliferation [23]. Thus, the 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Inhibition of cell proliferation in human MCF-7 breast cancer cells by 40 µM pyrrolobenzoxazepines and PK 11195. 
Experimental data represent mean ± SEM of at least three independent experiments. ** p<0.01; *** p<0.001, significantly 
different from PK 11195 using one-way ANOVA and Bonferroni’s post-hoc test. All ligands inhibited cell proliferation significantly 
better than the vehicle-treated control (p<0.001). 
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pyrrolobenzoxazepines which inhibit cell proliferation 
may act as TSPO antagonists, inhibiting TSPO-
mediated cell proliferation and growth. Alternatively, 
TSPO ligands may exert their anti-tumor effects by 
inducing apoptosis, as PK 11195 is able to induce 
mitochondrial release of cytochrome c, and ultimately 
cause mitochondrial uncoupling [23]. 
Pyrrolobenzoxazepines have been shown previously to 
reduce tumor cell growth in human cell lines through 
the induction of the caspase-3 family of proteases [5] 
and induction of G1 cell cycle arrest. 
Despite the ability of the pyrrolobenzoxazepines to 
elicit a range of functional effects, no correlation 
between binding profile and the ability of the ligands to 
modulate pregnenolone and NO release, or the anti-
proliferative properties of the compounds was revealed. 
For example, compounds 5 and 6 were both high 
affinity ligands with a Hill slope of 1.0, caused no 
stimulation of steroid synthesis, but inhibited cell 
proliferation to a degree comparable to 1-3, which 
increased steroid synthesis significantly and had Hill 
slopes of 0.99, 0.75, and 0.93 in rat, respectively. The 
absence of a correlation between binding affinity and 
functional profile has also been observed with other 
TSPO ligands [13, 18]. 
We propose that the lack of correlation between 
binding and functional assays may be partly attributed 
to the marked differences observed in ligand binding 
across species. However, the binding profile observed 
in rodent did not correlate to the functional assays in 
rodent cell lines measuring steroid production or NO 
release. Likewise, the binding profile in human did not 
correlate to the anti-proliferative effects observed in 
human MCF-7 breast cancer cells. Thus, while TSPO 
functional activity is traditionally denoted by 
pregnenolone production in rat C6 glioma cells at a 
ligand concentration of 40µM, this may not be a true 
indication of solely TSPO-mediated effects. More 
recent studies suggest that testing ligands at 
nanomolar concentrations consistent with their binding 
affinities mediate very different functional effects 
compared to those assays performed at micromolar 
concentrations, whereby effects may be TSPO-
independent [24]. Alternatively, recent evidence 
suggests that TSPO ligand binding varies across 
different tissues [25]. The existence of species 
differences also questions the validity of functional 
assays in rodent for predicting therapeutic outcomes 
relevant to human disease. 
The current study provides evidence for a complex 
binding interaction at TSPO, and uncovers marked 
species differences between rat and human TSPO 
ligand binding, thus questioning the suitability of current 
binding and functional assays undertaken in rat tissues 
for the translation to human studies. While we have 
identified ligands with potential therapeutic effects, the 
lack of correlation to binding profile suggests currently 
accepted functional assays need to be optimized to 
take into account dose-related effects, and tissue and 
species disparity of binding sites. While the current 
TSPO pharmacophore can assist in the development of 
selective high affinity ligands [1], there exists no 
consideration of binding site cooperativity or clear 
understanding of structural residues important for 
mediating downstream functional effects. The 
development of structure-activity relationships for 
TSPO ligand binding needs to take into account 
binding site cooperativity and the existence of species 
and tissue disparity, which will aid in the rational 
development of TSPO-based therapeutic drugs. 
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